The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Novel Antiviral Drugs-Global Market Insights and Sales Trends 2024
Synopsis
The mechanism of action of antiviral drugs is mainly to inhibit the entry of viral particles into host cells and to inhibit the early stages of viral replication. There is also an inhibitor of DNA polymerase, which is mainly due to its ability to inhibit viral coding. At present, new antiviral drugs are actively seeking host factors, both in the initial stage of viral infection and in the later stages of nuclear transport of viral RNP complexes, to produce new drugs with new modes of action without drug resistance.
The global Novel Antiviral Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Novel Antiviral Drugs in various end use industries. The expanding demands from the Hepatitis Therapeutics, HIV/AIDS Therapeutics, Herpes Therapeutics and Influenza Therapeutics, are propelling Novel Antiviral Drugs market. Reverse Transcriptase Inhibitors, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Protease Inhibitors segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Novel Antiviral Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Novel Antiviral Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Novel Antiviral Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Novel Antiviral Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Novel Antiviral Drugs covered in this report include Roche Holding AG, GlaxoSmithKline, Bristol-Myers Squibb, AbbVie, Johnson & Johnson, Merck & Co, Novartis, Dr Reddy’s and Gilead Sciences, etc.
The global Novel Antiviral Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Roche Holding AG
GlaxoSmithKline
Bristol-Myers Squibb
AbbVie
Johnson & Johnson
Merck & Co
Novartis
Dr Reddy’s
Gilead Sciences
Aurobindo Pharma
Cipla
Global Novel Antiviral Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Novel Antiviral Drugs market, Segment by Type:
Reverse Transcriptase Inhibitors
Protease Inhibitors
Fusion Inhibitors
Immune System Modulators
Other
Global Novel Antiviral Drugs market, by Application
Hepatitis Therapeutics
HIV/AIDS Therapeutics
Herpes Therapeutics
Influenza Therapeutics
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Novel Antiviral Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The mechanism of action of antiviral drugs is mainly to inhibit the entry of viral particles into host cells and to inhibit the early stages of viral replication. There is also an inhibitor of DNA polymerase, which is mainly due to its ability to inhibit viral coding. At present, new antiviral drugs are actively seeking host factors, both in the initial stage of viral infection and in the later stages of nuclear transport of viral RNP complexes, to produce new drugs with new modes of action without drug resistance.
The global Novel Antiviral Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Novel Antiviral Drugs in various end use industries. The expanding demands from the Hepatitis Therapeutics, HIV/AIDS Therapeutics, Herpes Therapeutics and Influenza Therapeutics, are propelling Novel Antiviral Drugs market. Reverse Transcriptase Inhibitors, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Protease Inhibitors segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Novel Antiviral Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Novel Antiviral Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Novel Antiviral Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Novel Antiviral Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Novel Antiviral Drugs covered in this report include Roche Holding AG, GlaxoSmithKline, Bristol-Myers Squibb, AbbVie, Johnson & Johnson, Merck & Co, Novartis, Dr Reddy’s and Gilead Sciences, etc.
The global Novel Antiviral Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Roche Holding AG
GlaxoSmithKline
Bristol-Myers Squibb
AbbVie
Johnson & Johnson
Merck & Co
Novartis
Dr Reddy’s
Gilead Sciences
Aurobindo Pharma
Cipla
Global Novel Antiviral Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Novel Antiviral Drugs market, Segment by Type:
Reverse Transcriptase Inhibitors
Protease Inhibitors
Fusion Inhibitors
Immune System Modulators
Other
Global Novel Antiviral Drugs market, by Application
Hepatitis Therapeutics
HIV/AIDS Therapeutics
Herpes Therapeutics
Influenza Therapeutics
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Novel Antiviral Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Novel Antiviral Drugs
1.1 Novel Antiviral Drugs Market Overview
1.1.1 Novel Antiviral Drugs Product Scope
1.1.2 Novel Antiviral Drugs Market Status and Outlook
1.2 Global Novel Antiviral Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Novel Antiviral Drugs Market Size by Region (2018-2029)
1.4 Global Novel Antiviral Drugs Historic Market Size by Region (2018-2023)
1.5 Global Novel Antiviral Drugs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Novel Antiviral Drugs Market Size (2018-2029)
1.6.1 North America Novel Antiviral Drugs Market Size (2018-2029)
1.6.2 Europe Novel Antiviral Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific Novel Antiviral Drugs Market Size (2018-2029)
1.6.4 Latin America Novel Antiviral Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa Novel Antiviral Drugs Market Size (2018-2029)
2 Novel Antiviral Drugs Market by Type
2.1 Introduction
2.1.1 Reverse Transcriptase Inhibitors
2.1.2 Protease Inhibitors
2.1.3 Fusion Inhibitors
2.1.4 Immune System Modulators
2.1.5 Other
2.2 Global Novel Antiviral Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Novel Antiviral Drugs Historic Market Size by Type (2018-2023)
2.2.2 Global Novel Antiviral Drugs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Novel Antiviral Drugs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Novel Antiviral Drugs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Novel Antiviral Drugs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Novel Antiviral Drugs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Novel Antiviral Drugs Revenue Breakdown by Type (2018-2029)
3 Novel Antiviral Drugs Market Overview by Application
3.1 Introduction
3.1.1 Hepatitis Therapeutics
3.1.2 HIV/AIDS Therapeutics
3.1.3 Herpes Therapeutics
3.1.4 Influenza Therapeutics
3.1.5 Other
3.2 Global Novel Antiviral Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Novel Antiviral Drugs Historic Market Size by Application (2018-2023)
3.2.2 Global Novel Antiviral Drugs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Novel Antiviral Drugs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Novel Antiviral Drugs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Novel Antiviral Drugs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Novel Antiviral Drugs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Novel Antiviral Drugs Revenue Breakdown by Application (2018-2029)
4 Novel Antiviral Drugs Competition Analysis by Players
4.1 Global Novel Antiviral Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Novel Antiviral Drugs as of 2022)
4.3 Date of Key Players Enter into Novel Antiviral Drugs Market
4.4 Global Top Players Novel Antiviral Drugs Headquarters and Area Served
4.5 Key Players Novel Antiviral Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Novel Antiviral Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Roche Holding AG
5.1.1 Roche Holding AG Profile
5.1.2 Roche Holding AG Main Business
5.1.3 Roche Holding AG Novel Antiviral Drugs Products, Services and Solutions
5.1.4 Roche Holding AG Novel Antiviral Drugs Revenue (US$ Million) & (2018-2023)
5.1.5 Roche Holding AG Recent Developments
5.2 GlaxoSmithKline
5.2.1 GlaxoSmithKline Profile
5.2.2 GlaxoSmithKline Main Business
5.2.3 GlaxoSmithKline Novel Antiviral Drugs Products, Services and Solutions
5.2.4 GlaxoSmithKline Novel Antiviral Drugs Revenue (US$ Million) & (2018-2023)
5.2.5 GlaxoSmithKline Recent Developments
5.3 Bristol-Myers Squibb
5.3.1 Bristol-Myers Squibb Profile
5.3.2 Bristol-Myers Squibb Main Business
5.3.3 Bristol-Myers Squibb Novel Antiviral Drugs Products, Services and Solutions
5.3.4 Bristol-Myers Squibb Novel Antiviral Drugs Revenue (US$ Million) & (2018-2023)
5.3.5 AbbVie Recent Developments
5.4 AbbVie
5.4.1 AbbVie Profile
5.4.2 AbbVie Main Business
5.4.3 AbbVie Novel Antiviral Drugs Products, Services and Solutions
5.4.4 AbbVie Novel Antiviral Drugs Revenue (US$ Million) & (2018-2023)
5.4.5 AbbVie Recent Developments
5.5 Johnson & Johnson
5.5.1 Johnson & Johnson Profile
5.5.2 Johnson & Johnson Main Business
5.5.3 Johnson & Johnson Novel Antiviral Drugs Products, Services and Solutions
5.5.4 Johnson & Johnson Novel Antiviral Drugs Revenue (US$ Million) & (2018-2023)
5.5.5 Johnson & Johnson Recent Developments
5.6 Merck & Co
5.6.1 Merck & Co Profile
5.6.2 Merck & Co Main Business
5.6.3 Merck & Co Novel Antiviral Drugs Products, Services and Solutions
5.6.4 Merck & Co Novel Antiviral Drugs Revenue (US$ Million) & (2018-2023)
5.6.5 Merck & Co Recent Developments
5.7 Novartis
5.7.1 Novartis Profile
5.7.2 Novartis Main Business
5.7.3 Novartis Novel Antiviral Drugs Products, Services and Solutions
5.7.4 Novartis Novel Antiviral Drugs Revenue (US$ Million) & (2018-2023)
5.7.5 Novartis Recent Developments
5.8 Dr Reddy’s
5.8.1 Dr Reddy’s Profile
5.8.2 Dr Reddy’s Main Business
5.8.3 Dr Reddy’s Novel Antiviral Drugs Products, Services and Solutions
5.8.4 Dr Reddy’s Novel Antiviral Drugs Revenue (US$ Million) & (2018-2023)
5.8.5 Dr Reddy’s Recent Developments
5.9 Gilead Sciences
5.9.1 Gilead Sciences Profile
5.9.2 Gilead Sciences Main Business
5.9.3 Gilead Sciences Novel Antiviral Drugs Products, Services and Solutions
5.9.4 Gilead Sciences Novel Antiviral Drugs Revenue (US$ Million) & (2018-2023)
5.9.5 Gilead Sciences Recent Developments
5.10 Aurobindo Pharma
5.10.1 Aurobindo Pharma Profile
5.10.2 Aurobindo Pharma Main Business
5.10.3 Aurobindo Pharma Novel Antiviral Drugs Products, Services and Solutions
5.10.4 Aurobindo Pharma Novel Antiviral Drugs Revenue (US$ Million) & (2018-2023)
5.10.5 Aurobindo Pharma Recent Developments
5.11 Cipla
5.11.1 Cipla Profile
5.11.2 Cipla Main Business
5.11.3 Cipla Novel Antiviral Drugs Products, Services and Solutions
5.11.4 Cipla Novel Antiviral Drugs Revenue (US$ Million) & (2018-2023)
5.11.5 Cipla Recent Developments
6 North America
6.1 North America Novel Antiviral Drugs Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Novel Antiviral Drugs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Novel Antiviral Drugs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Novel Antiviral Drugs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Novel Antiviral Drugs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Novel Antiviral Drugs Market Dynamics
11.1 Novel Antiviral Drugs Industry Trends
11.2 Novel Antiviral Drugs Market Drivers
11.3 Novel Antiviral Drugs Market Challenges
11.4 Novel Antiviral Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
